1	A rapid CRISPR/Cas12a-based assay for the detection of HIV-1 Indian Clade-C infections
2	
3	Anjli Gaur ^{1*} , Harsh Bhakhri ^{1*} , Nitesh Mishra ^{1,4\$} , Shaifali Sharma ^{1\$} , Tanu Bansal ¹ , Mani
4	Kalaivani ⁶ , Megha Brijwal ⁵ , Bimal Kumar Das ² , Rakesh Lodha ³ , Subrata Sinha ^{1#} , Kalpana
5	Luthra ^{1#}
6	
7	Affiliation:
8	1. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India 110029.
9 10	2. Department of Microbiology, All India Institute of Medical Sciences, New Deini, India 110029.
11	3. Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India 110029.
12	4. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA,
13	United States.
14	5. Virology Section, Department of Microbiology, All India Institute of Medical Sciences, New
15	Delhi, India 110029.
16 17	6. Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India 110029.
10	* These outhors contributed equally (charad first outhors)
10	^{\$} These authors contributed equally (shared second authors).
20	# Corresponding Authors: sub_sinha@hotmail.com_kalpanaluthra@gmail.com
20	"Conceptioning Authors: Sub_shind Ghounan.com, Kaipananauna@ginan.com
21	A bratwo at
22	Adstract
23	Early detection of HIV-1 infection is crucial to initiate anti-retroviral therapy (ART) to suppress
24	viremia and disease progression. Herein, we developed a CRISPR/Cas12a-based HIV-1 detection
25	assay by optimizing components for a coupled isothermal preamplification by recombinase
26	polymerase amplification (RPA). The HIV-1 Indian Clade-C-specific conserved pol region was

- 27 targeted by crRNA designed for Clade-specific detection. The CRISPR/Cas12a cleavage of the
- viral cDNA input is displayed as a single visually detectable outcome due to the collateral cleavage
- of the ssDNA-FAM-BQ reporter, enabling the rapid detection of HIV-1. The performance of the
- 30 assay was evaluated by testing sera of 41 Indian Clade C HIV-1 seropositive individuals, which
- 31 included 28 HIV-1 infected infant samples, HIV-1 Indian clade C genome plasmid, viral disease
- control DNA/RNA samples (Influenza, RSV, Parvovirus, HPIV, CMV, and HBV), and 31 healthy
 donor sera samples. With 96% sensitivity and 92.65% specificity for HIV-1C detection, with
- fluorescence and visual readout, and a capability of detection using lateral flow dipsticks, our
- 35 CRISPR/Cas12a-based HIV-1 C detection assay demonstrates the potential to be developed into a
- 36 robust point-of-care molecular diagnostic test for HIV-1C. Moreover, it may serve as a potential
- 37 rapid NAT alternative in detecting mother-to-child transmission (MCT) of HIV-1C in infants (<2
- 38 years of age), where rapid antibody-based serology tests are rendered ineffective due to the
- 39 presence of maternal antibodies.

It is made available under a CC-BY-NC-ND 4.0 International license .

40 Introduction

Human immunodeficiency virus (HIV-1) is an infectious entity that can lead to the development 41 of acute immunodeficiency syndrome (AIDS) in an infected individual. According to the UNAIDS 42 global HIV-1 statistics, 39 million people globally were living with HIV-1. In 2022, 6,30,000 43 people died from AIDS-related illness (1). HIV-1 Clade C, being responsible for half of the global 44 infections, accounts for 97% of HIV-1 infections in India (2). HIV-1 infections remain to be one 45 of the global public health issues, with an effective vaccine still elusive, lifelong adherence to 46 antiretroviral drugs is required for the effective management of the disease (3). Hence, early 47 detection of HIV-1 is crucial for treatment initiation, prevention of transmission, and disease 48 progression in perinatally infected infants, children, and adults (4). 49

The quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) is one of the sensitive 50 nucleic acid tests to detect HIV-1 in samples with low viral RNA copies. Its high sensitivity and 51 specificity have been considered a "gold standard" for disease diagnostics, with several approved 52 53 qRT-PCR tests for HIV-1 (5-9). However, this method is not cost-effective for HIV-1 detection in resource-limited settings. In recent decades, several isothermal amplification methods, such as 54 loop-mediated isothermal amplification (LAMP), have been developed as attractive alternatives to 55 conventional PCR methods because of their simplicity, rapidity, and low cost. However, deploying 56 LAMPs as efficient POC diagnostics for clinical applications is still challenging due to complex 57 assay design and primer set optimizations requiring a trained professional (10). For the diagnosis 58 of HIV-1 infection in infants and children less than 18 months of age, National AIDS Control 59 60 Organization (NACO, India) recommends the use of a Total Nucleic Acid PCR test on a Dried 61 Blood spot (DBS) sample of the infant to detect viral nucleic acid for diagnosis of HIV-1 infection during infancy. Serology testing is not preferred in infants and children of this age group due to 62 plausible interference by the transplacental passage of maternal antibodies in the infant (11–13) 63 64

With advances in CRISPR/Cas-based technology, its cost-effectiveness, high sensitivity, and 65 specificity for its target sequence provides a platform for using the CRISPR/Cas-based systems in 66 molecular diagnostics (14). Recently, RNA-guided CRISPR/Cas nuclease-based nucleic acid 67 detection has shown great promise for developing next-generation molecular diagnostics 68 technology due to its high sensitivity, specificity, and reliability. For example, some Cas nucleases 69 (e.g., Cas12a, Cas12b, and Cas13a) perform intense collateral cleavage activities in which a 70 crRNA-target binding activated Cas can indiscriminately cleave surrounding non-target single-71 72 stranded nucleic acids (15–18). By combining with a sensitive isothermal preamplification at 37°C using recombinase polymerase amplification (RPA) (19-21), Cas13 and Cas12a have, 73 respectively, been used to develop SHERLOCK (Specific High-sensitivity Enzymatic Reporter 74 UnLOCKing) system and DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter) 75 system for highly sensitive nucleic acid detection (22,23). Apart from the RPA method, some 76 CRISPR-Cas-based nucleic acid sensors utilized the LAMP and PCR approaches, such as the 77 78 CRISPR-Cas12b-assisted HOLMESv2 platform (24,25). The CRISPR/Cas systems, such as the

- 79 CRISPR/Cas9, CRISPR/Cas12, and CRISPR/Cas13, are described for the detection of various
- viral nucleic acids viz, Zika virus, Ebola virus, Dengue virus, SARS-CoV2, and HBV (26–33).
- 81 In the present study, we developed a sensitive CRISPR/Cas12a-based assay for rapid and specific
- 82 detection of HIV-1 Indian clade C, being the most prevalent infecting HIV-1 clade in India. A
- crRNA targeting the conserved pol regions in the HIV-1 Indian clade C genome was used for the
- 84 specific detection. The assay components were optimized for isothermal nucleic acid amplification
- by RPA and CRISPR/Cas12a-based cleavage reaction to occur in a single tube at 39 °C for 45 min,
- 86 thereby eliminating the need for an intermediate nucleic acid purification step. The assay is
- 87 adaptable for versatile detection modes, such as visual (UV transilluminator), Fluorescence
- 88 intensity readout, and Lateral flow dipstick-based readout. Herein, we have developed a rapid and
- 89 sensitive CRISPR/Cas12a-based HIV-1 C detection assay that demonstrates the ability to detect
- 90 HIV-1 infection in infants, with the potential to be developed into a sensitive lateral flow-based
- 91 point-of-care molecular diagnostic test for HIV-1 Clade-C.

It is made available under a CC-BY-NC-ND 4.0 International license .

Material and methods 92

Clinical samples and ethical statement 93

A total of 41 HIV-1 positive donor sera (including 28 infant sera) and 31 healthy donor sera, 94 separated from blood samples that were collected from the Department of Pediatrics and 95 Department of Microbiology, AIIMS New Delhi, India, were included in this study. All the donors 96 were ART-naïve at the time of diagnosis and were not showing symptoms of AIDS progression. 97 The detailed demographics and immunological profile (Table S1) were obtained from the 98 Department of Microbiology, AIIMS New Delhi, India. Written informed consent was obtained 99 100 from the parent/LAR of the infants/children. The study was reviewed and approved by the 101 Institutional Ethics Committee (IEC) of All India Institute of Medical Sciences (IEC-114/06.03.2020), RP-47/2020. The demographic profile of the study participants was recorded 102 systematically. DNA/RNA samples of Influenza, Respiratory syncytial virus (RSV), Parvovirus, 103 104 Human Parainfluenza virus (HPIV), and Cytomegalovirus (CMV) were obtained from the Virology Testing Laboratory, Department of Microbiology, AIIMS New Delhi and used as disease 105 controls. The HIV-1 genome plasmid 93IN999 and 93IN905(positive control) and HIV-1 Clade B 106 infected donor sera samples (disease control) were obtained from the NIH AIDS reagent program. 107

108

109 HIV-1 RNA extraction and cDNA synthesis

Viral RNA was extracted from 140 µl of serum using the QIAamp Viral RNA Mini Kit according 110 to the manufacturer's instructions. Immediately after RNA extraction, reverse transcription was 111 performed gene-specific OFM19 112 using the primer (5'-GCACTCAAGGCAAGCTTTATTGAGGCTTA-3') and Superscript IV reverse transcriptase 113 (Thermo Scientific). The procedure of viral extraction to cDNA preparation using Superscript IV 114 reverse transcriptase was performed within a one-hour duration. 115

116

117 crRNA and RPA primer designing

118 crRNA sequence for HIV-1 clade C viruses in the pol region was designed. A total of 86 HIV-1 Clade sequences obtained from 119 С were the HIV database (https://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html). The sequences obtained were 120 121 aligned on MEGAX to generate a multiple sequence alignment (MSA). The Consensus maker tool at the LANL HIV database was used to create the consensus sequence of the pol region (Figure 122 S1). The consensus sequences within the pol region were scanned across the MSA of Indian pol 123 using the Analyse-ALIGN tool at LANL HIV database for maximum conserved regions. Regions 124 with maximum conservation were used as crRNA target sequences. One consideration for crRNA 125 126 design for CRISPR/Cas12a-based detection assay is the lack of overlap with RPA amplicon 127 primers, as overlap with primers may result in false positives. The identified conserved region was picked as the crRNA target, and along with a Cas12a adaptor sequence, the crRNA was synthesized 128 from IDT (Integrated DNA Technologies). The flanking conserved regions were identified to 129 design RPA primers with optimal conditions: size range within 30-35 and Tm range between 37°C-130 42°C. A primer pair was designed to amplify 183 bp RPA amplicon, which carries the crRNA target 131

It is made available under a CC-BY-NC-ND 4.0 International license .

- 132 sequence RPA_Forward (5'-ACAGGRGCAGATGATACAGTATTAGAAGA-3') and
 133 RPA_Reverse (5'-CCAATTATGTTGAYAGGTGTDGGTCC-3').
- 134

135 Probe design for fluorescence and lateral flow-based detection:

- The ssDNA-FAM-BQ reporter, a five-nucleotide oligonucleotide (5'-TTATT-3') labelled by a 5' 6-FAM (Fluorescein) fluorophore and a 3' Iowa Black® FQ quencher- ssDNA-FAM-BQ probe (IDT) was designed and synthesized for fluorescence/visual readout. Upon the detection of the HIV-1 pol sequence by the CRISPR/Cas12a complex, the collateral cleavage activity cleaves the ssDNA-FAM-BQ, which releases the FAM molecule from the quencher, and the signal generated was detected using a UV transilluminator/lamp and fluorescence reader. The ssDNA probe with the same sequence as for fluorescence readout was used with 5' FAM, and 3' Biotin was designed
- 143 and synthesized for lateral flow strip-based assay readout.
- 144

145 The CRISPR/Cas12a-based assay reaction

146 The RPA reactions were performed using the TwistAmp Basic kit (TwistDx) as instructed by the 147 manufacturer. For the CRISPR/Cas12a reaction, purified LbaCAs12a (IDT) was used. The assay 148 was set up with RPA reagents with optimized concentrations (Figure S3 and S4):1X rehydrated 149 Master mix, RPA primers (IDT) (168nM), and 14 mM MgOAc) and CRISPR/Cas12a cleavage 150 reaction reagents: LbaCas12a (0.64 μ M), crRNA(0.64 μ M), 1X Cas12 activity Buffer (IDT), 151 ssDNA-FAM-BQ fluorescent probe (8 μ M) into a single tube. The reaction was incubated at 39°C 152 for 45 min.

153

154 Visual, fluorescence, and lateral flow dipstick-based readouts of the assay

The end-point fluorescence signal detection was done using a UV lamp/transilluminator (visual 155 detection) and fluorescence detection by a fluorometer. The emission was recorded as AFU 156 157 (Arbitrary fluorescence unit) at excitation at 488nm and emission at 520nm. For adapting the assay as a lateral flow strip-based CRISPR/Cas12a detection assay, the same reaction was set up with 158 the ssDNA-FAM-Biotin probe with the optimized concentration (0.009 µM) such that there is no 159 non-specific detection at the test line (Figure S6). Post incubation, 10µl the reaction mix was 160 applied to the lateral flow dipsticks (HybriDetect - Universal Lateral Flow Assay Kit). The 161 dipsticks were dipped into 100µl of the HybriDetect assay buffer provided with the kit. The assay 162 buffer was allowed to adsorb for 2-3mins and colour development on the test and control line was 163 observed to determine a positive or negative reaction. 164

165

166 Statistical analysis

167 All the statistical analyses were performed using Python (version 3.9). The sensitivity and 168 specificity of the diagnostic assay were calculated using the scikit-learn library. To distinguish

between positive and negative HIV-1 detection using the assay, the optimal AFU threshold value

- for the fluorescence readout was determined by plotting the ROC curve and calculating AUC and
- 171 Youden's Index by using the 'roc curve' and 'auc' function of the 'scikit-learn' library. The

It is made available under a CC-BY-NC-ND 4.0 International license .

- percentage sensitivity and specificity of the assay were computed using the 'confusion_matrix'
- 173 function of the scikit-learn library. The Clopper-Pearson confidence intervals for specificity and
- sensitivity percentages were calculated using the 'binom' function by fitting a binomial distribution
- 175 for 95% confidence. Cohen's Kappa coefficient was also calculated to assess the agreement
- 176 between the assay results and the true labels, accounting for chance agreement, using the
- 177 'cohen kappa score' function from the same library. Data plotting was performed using the
- 178 GraphPad Prism software (Version 9.0; La Jolla, CA, USA).
- 179

180 Data availability

- 181 All the data to support the findings of the study are available within the paper and supplementary
- information. Any additional information can be requested from the corresponding authors. The
- source data for the endpoint fluorescence readout and assay performance evaluation are provided
- 184 as Source Data File of this paper.

It is made available under a CC-BY-NC-ND 4.0 International license .

185 **Results**

186 The CRISPR/Cas12a-based assay system.

In this study, we developed and evaluated a CRISPR/Cas12a-based assay system for the rapid 187 detection of HIV-1 Clade C viral nucleic acid in serum samples. In the assay, the preamplification 188 step by recombinase polymerase amplification (RPA) and cleavage by CRISPR/Cas12a 189 190 recognition and subsequent cleavage of ssDNA-FAM-BQ reporter to give a detectable fluorescence signal as output was standardized to work as a coupled reaction in a single tube 191 192 (Figure 1a). The assay utilized a crRNA that targeted a conserved HIV-1 C pol region within the RPA amplicon (Figure 1b). The cas12a and crRNA were added into the reaction solution 193 194 containing the RPA primers, recombinase, single-stranded DNA binding protein (SSB), stranddisplacement DNA polymerase, single-stranded DNA fluorophore-quencher (ssDNA-FAM-BQ) 195 reporter and target template. During the incubation of the assay reaction at 39°C for 45 minutes, 196 the RPA amplification was initiated, and the activity of the strand displacement DNA polymerase 197 198 determined the target sites for the cas12a-crRNA complex. The binding of the Cas12a-crRNA complexes with the target sites on the amplified viral DNA led to activation of the collateral 199 200 cleavage activity of Cas12a endonuclease and cleavage of the ssDNA-FAM-BQ reporter 201 molecules, generating a strong fluorescence signal. Thus, the amplified target sequences generated during the RPA triggered CRISPR/Cas12a-based collateral cleavage activity in this assay. 202 Previous studies have demonstrated that the collateral cleavage activity of the CRISPR/Cas12a 203 system is independent of target strand cleavage, showing that the collateral cleavage of ssDNA-204 FAM-BO reporters by the Cas12a nuclease is triggered by the binding of crRNA to target sites 205 (16,17). The fluorescence signal from the cleaved ssDNA-FAM-BQ reporter was detected using a 206 207 UV transilluminator for a rapid qualitative assertion of the assay results or by taking the fluorescence readout as arbitrary fluorescence units (AFU) by a fluorescence reader at an 208 209 excitation of 488nm and emission of 520nm, for a more accurate/semi-quantitative assertion of assay results and distinguish between a positive or negative CRISPR/Cas12a based cleavage 210 reaction, hence presence or absence of HIV-1 clade C nucleic acid in the sample evaluated (Figure 211 212 1a).

213

214 Design and optimization of the CRISPR/Cas12a-based assay system.

Various components were designed for the CRISPR/Cas12a-based detection assay to work in sync 215 with the coupled isothermal RPA reaction, and concentrations were optimized for distinct positive 216 217 vs. negative results. Firstly, the crRNA was designed to target the HIV-1 clade C sequence. The crRNA in the assay was designed to target the most conserved region of the HIV-1 Indian Clade 218 C sequences. Upon multiple sequence alignment of 86 Indian Clade C sequences, we identified 219 the Pol region of the HIV-1 genome as the most conserved region (Figure S1a-b). The crRNA was 220 designed by taking 21bps of the conserved region sequence (2453-2475 HXB2 coordinate) 221 downstream to the PAM sequence (TTTV) along with the Cas12a binding adaptor sequence 222 (Figure S2a-b). To detect the specific region by Cas12a cleavage, preamplification by RPA was 223 done by designing RPA primers using the conserved regions to amplify a 183bp RPA amplicon 224

It is made available under a CC-BY-NC-ND 4.0 International license .

(Figure S3a), which lies in the Pol gene sequence at the location from 2328 to 2509 in the HXB2 225 genome map (Los Alamos). The primers were designed by keeping the range of the number of 226 nucleotides within 30-35 and Tm in between 37°C-42°C (Figure 1b). Further, we optimized the 227 RPA reaction for various parameters: reaction time, primer concentration, and sample cDNA 228 amount. Multiple reactions were set up to determine the optimal time for RPA by incubation at 229 different time points from 20 minutes to 40 minutes, with an increment of 5 minutes. An incubation 230 of 30-40 mins was optimal for amplifying the HIV-1 amplicon (Figure S3b). RPA reactions with 231 a gradient of primer concentrations were performed to determine the optimal primer concentration. 232 Optimal amplification was observed at a primer concentration of 168nM (Figure S2c). To 233 determine the patient's cDNA dilution to perform RPA, an HIV-infected infant donor cDNA 234 sample of AIIMS748 was tested from neat to 1:20 cDNA dilutions. Low amplicon band intensity 235 was observed at neat and 1:5 cDNA dilution, with a darker band intensity at 1:10 and 1:20 cDNA 236 dilution depicting hindrance of cDNA component at lower dilution with optimal detection at a 237 238 higher cDNA dilution (Figure S3d). The CRISPR/Cas12a-based cleavage assay was optimized for the detection of HIV-1 in clinical samples. The ssDNA-FAM-BQ reporter concentration (8 µM) 239 and the ratio of crRNA to cas12a (0.64nM) (1:1) were used for the CRISPR/Cas12a-based 240 cleavage reaction (29). For a coupled RPA and CRISPR/Cas12a-based cleavage for detection of 241 242 HIV-1 target sequence, all the above-optimized assay components were incubated at 39°C for 45 minutes for all the amplified sequences to be cleaved simultaneously. The CRISPR/Cas12a-based 243 HIV-1 detection assay was performed for HIV-1 clade C genome plasmids 93IN999 and 93IN905 244 (10 ng each), and multiple cDNA dilutions from one HIV-1 positive infant donor AIIMS748 were 245 used for the optimization of the assay. Corroborating with the RPA amplification of patient viral 246 247 cDNA, a cDNA dilution of 1:10 yielded a better detectable fluorescence and visual readout signal (UV transilluminator) (Figure 2a-b). Hence, all the HIV-positive patients' viral cDNA 248 samples were tested at a minimum of 1:10 cDNA dilution. 249

250

Evaluation of sensitivity and specificity of the CRISPR/Cas12a-based HIV-1 C detection assay in clinical samples.

253 The high sensitivity and specificity of an assay are a testament to its effectiveness. We evaluated the sensitivity and specificity of our assay using 'True Positives' and 'True Negatives' as test 254 samples. True positives comprised of the cDNA samples from 41 HIV-1 positive donor sera and 9 255 256 replicate samples of HIV-1 genome plasmid 93IN999 and 93IN905. True negatives comprised of cDNA samples from 31 healthy donor sera, viral DNA/RNA samples of 15 viral disease controls 257 (1-Influenza, 1-RSV, 1-Parvovirus, 1-HPIV, 3-CMV, and 5-HBV genome plasmids), and 25 non-258 template control (NTCs) replicates (Figure 3a). Firstly, the Receiver operating characteristic 259 (ROC) curves using the arbitrary fluorescence unit (AFU) values for the various samples tested 260 were plotted to distinguish between the positive and negative results of the assay and determine 261 the optimal AFU threshold values. The ROC curves were plotted separately for positive and 262 different negative sample groups: positive vs healthy controls, positive vs negative controls 263 (NTCs), positive vs healthy and negative controls, and positive vs disease controls. The area under 264 the curve (AUC) and Youden's Index were calculated for each ROC curve to determine the optimal 265

It is made available under a CC-BY-NC-ND 4.0 International license .

AFU threshold values of fluorescence readout above which any sample tested can be classified as 266 positive for the assay. Optimal AFU threshold values to determine test positivity in the context of 267 268 the different controls; 341 (positive vs healthy-AUC 1.00), 725 (positive vs NTCs-AUC 0.992), 596 (positive vs healthy and NTCs-AUC 0.996) and 800 (positive vs disease controls-AUC 0.958) 269 (Figure 2c-f). Since we observed an overlap between some of the positive samples with the lowest 270 AFU and that of the highest AFU of a few negative samples, we defined the sensitivity and 271 specificity of the assay by taking into account all the different AFU threshold values obtained. The 272 AFU threshold of 725 yielded a maximum sensitivity and specificity of 94% and 97.03%, 273 respectively, that led to 3 false negatives (FN) and 2 false positives (FP) (Figure 3d). The AFU 274 threshold of 596 yielded 96% sensitivity and 92.65% specificity, with 2 FNs and 5 FPs (Figure 275 3e). The lowest and highest AFU threshold values, 341 and 800, result in compromised specificity 276 and sensitivity, respectively (Figure 3c, 3f). Using the AFU threshold of 341 yielded 0 FNs but 15 277 278 FPs, mostly from viral disease controls and NTCs values, suggesting that this threshold value could serve as a good baseline for screening for HIV-1C in a population. Also, AFU threshold of 800 279 vielded 0 FPs but 6 FNs, and could serve as an ideal AFU threshold, as any value above this 280 threshold may confirm the presence of HIV-1C nucleic acid. Based on these observations, we 281 defined a range of AFU threshold of 341-800, with AFU values of test samples <341 and >800 282 would be described as negative and positive for the assay respectively, while samples with AFU 283 values between 341-800 would be reported as inconclusive, with a need for reassessment and 284 285 validation (Figure 3b).

To evaluate the assay performance and determine the sensitivity and specificity, an AFU threshold 286 of 596 was selected, as it yielded the least FNs with high specificity and sensitivity values of 96% 287 and 92.65%, respectively, and a significant kappa value of 0.879 (Table 1). The viral cDNA 288 samples of 41 HIV-1 positive sera from clade C-infected infants/children and adults were tested in 289 the assay. Of the 41 samples, 22/41 were of known viral load, determined by gRT-PCR, and 19/41 290 were seropositive for HIV-1 IgG/IgM (with viral load not determined), which were included to 291 broaden the evaluation of the assay (Table S1). 35/41 positive clinical samples were tested positive, 292 and 6/41 positive samples were reported as inconclusive for the assay using the AFU threshold 293 range established (Figure S4a). Our findings demonstrated that the HIV-1C detection assay 294 developed herein possesses high sensitivity and specificity, affirming its effectiveness. The 295 CRISPR/Cas12a-based assay tested positive for the lowest viral load sample with 117000 296 297 copies/ml at a cDNA dilution of 1:10 from the donor AIIMS744 (Figure S4a, Table S1). Of the 41 298 cDNA samples of HIV-1 seropositive individuals tested, 28 were from infants (<2 years) (Table S1). With 27/28 HIV-1 positive infant samples tested positive using this assay and only 1/28 as 299 300 result inconclusive, the assay yielded a sensitivity of 96.43%, demonstrating the ability to 301 effectively detect HIV-1 in infant sera samples (Figure S4b). Serology-based methods are not 302 suitable for testing HIV-1 in infant samples due to the presence of of maternal antibodies. No visual 303 or fluorescence signal for the assay was observed in 31/31 cDNA samples from healthy controls demonstrating high specificity (Figure 4c). Furthermore, the specificity of the assay was validated 304 using viral disease control DNA/RNA samples from Influenza, Respiratory syncytial virus (RSV), 305 306 Parvovirus, Human Parainfluenza virus (HPIV), Cytomegalovirus (CMV), and Hepatitis B virus (HBV). While the UV transilluminator did not show a significant signal, the fluorescence readout 307 showed an AFU value in the range of 341-800 for most of the samples tested, hence falling in 308

It is made available under a CC-BY-NC-ND 4.0 International license .

result inconclusive criteria (Figure 4a). This depicts that with the presence of other viral nucleic 309 acid, there is an increase in the background fluorescence. Hence, while distinguishing between 310 311 HIV-1C and other viral diseases, samples with tested AFU value between 341-800 should be retested by RT-PCR prior to reporting for HIV-1 and other viral diseases. Further, we evaluated the 312 assay for the ability to discriminate HIV-1 Indian clade C from clade B HIV-1. The assay showed 313 314 specific detection of HIV-1 clade C in positive plasmid and HIV-1 positive donor cDNA sample AIIMS748, with no detection in 7 different clade B donor sera (Figure 4b). A positive signal for 315 HIV-1 clade C and no signal for HIV-1 clade B sequences demonstrates that the assay specifically 316 detects the major infecting HIV-1 Clade in India. Thus, our CRISPR-based HIV-1 Clade C 317 detection assay offers a simple, rapid, and visual approach to HIV-1 Clade C detection. 318

319

Adaptation of the CRISPR/Cas12a-based HIV-1 clade C detection assay as Lateral Flow Assay (LFA) for point-of-care diagnosis

The potential for point-of-care diagnostics is a promising aspect of our CRISPR/Cas12a-based 322 assay. Hence, the assay was adapted for the lateral flow dipstick-based detection of the cleaved 323 probe molecules. The ssDNA-FAM-Biotin probe has a 5'FAM molecule and 3'Biotin molecule; 324 all the probe molecules are captured at the control line via streptavidin-biotin interaction if there 325 is no collateral cleavage of the probe, while upon collateral cleavage of the probe in the presence 326 of target sequence, the FAM molecule is released and captured by the rabbit anti-FAM Ab gold 327 328 nanoparticles and sequestered on the test line via anti-rabbit antibodies leading to colour development (Figure 5a). Firstly, the ssDNA-FAM-Biotin probe concentration was optimized to 329 prevent any spillage of the probe onto the test line for a false positive detection. Using negative 330 control reactions (non-template controls (NTCs)), the concentration of the ssDNA-FAM-Biotin 331 probe was optimized using various dilutions, initially with a broad range of concentrations from 332 1.00µM to 0.00005µM. The concentration range of 0.0124 M to 0.0042 M showed the least non-333 specific detection at the test line (Figure S5a). A narrow range probe concentration between 0.0124 334 uM to 0.0042 uM was tested, and 0.0124M to 0.008 M showed the least non-specific test line 335 detection (Figure S5b). Furthermore, the non-specific detection was minimized by adding 5% 336 PEG6000 (based on the manufacturer's suggestions) (Figure S5c). The HIV-1 genome plasmid 337 (93IN999) was detected using probe concentrations of 0.0124 µM and 0.009 µM with 5% 338 PEG6000. The most optimal detection of the cleaved probe on the test line in a positive reaction 339 340 with minimal nonspecific detection in the NTC reaction was observed using 0.009 µM ssDNA-FAM-Biotin (Figure 5b, S5d). Overall, our study suggests the potential of the CRISPR/Ca12a-341 based HIV-1 clade C detection assay to be developed into point-of-care diagnostics of HIV-1, 342

instilling optimism about its future application.

It is made available under a CC-BY-NC-ND 4.0 International license .

344 Discussion

Early detection of viral infections aids in the effective management of the disease by allowing 345 timely interventions and preventing the spread. Major clinical laboratory tests for diagnosis of viral 346 347 infection are based on principles of immune assays, detection of viral antigens or specific antibodies in the test sample or on the principles of nucleic acid amplification and detection of 348 349 specific viral nucleic acid. Serology immune assays are rapid, point-of-care, and cost-effective tests but are not highly specific and sensitive; hence, they majorly serve the purpose of rapid 350 351 screening (34). Whereas Nucleic acid amplification tests (NAAT) such as PCR, quantitative PCR 352 (qPCR), reverse transcriptase PCR (RT-PCR) and reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) are robust, highly specific, and sensitive. Hence, they are reliable 353 354 confirmatory diagnostic methods but are costly and require sophisticated equipment (thermal cycler) and a trained technician, which is not practical in low-resource settings (10,35,36). 355

356 HIV-1 infections are one of the major global health concerns, with no known cure or vaccine and 357 lifetime adherence to anti-retroviral therapy being the only effective management strategy. The diagnostic strategies for HIV-1 involve the use of serum immune assays for rapid screening of 358 359 HIV-1 antigen or host antibodies, which is further confirmed by a qualitative PCR and viral load determination by qPCR for early initiation of ART and prevention of disease progression (5,8,37). 360 Although the 4th generation antibody and p24 antigen or combination laboratory immunoassays 361 are highly sensitive and evaluated and widely deployed, but in cases of acute HIV-1 infections, 362 antibody-based immunoassays may not be effective as seroconversion in case of HIV-1 may take 363 2-3 weeks. Although the patients show detectable levels of HIV-1 RNA and p24 during this period, 364 they remain negative for immunoassays. This leads to erroneous detections during this period as 365 the patients may have a high viral load, which leads to an increased risk of transmission (38–40). 366 Hence, NAAT-based laboratory diagnosis plays an important role in the detection of acute HIV in 367 combination with p24 and immunoassays. While these highly sensitive immunoassays and NAATs 368 for HIV-1 require a sophisticated laboratory setup, with costly equipment and trained technicians, 369 the surveillance and prevention of HIV-1 becomes less efficacious in low and middle-income 370 countries. There are emergence of various FDA-approved point-of-care rapid HIV-1 screening 371 tests, which detect anti-HIV IgG and IgM but fail in detecting acute HIV-1, with a 100% failure 372 373 rate in case of NAAT positive/seronegative samples (41). Hence, developing a rapid point-of-care assay for HIV-1 NAAT assay, which is specific, sensitive, and cost-effective, may aid in robust 374 HIV-1 detections and decrease the risk of spread. 375

Moreover, mother-to-child transmission (MCT) is even more difficult to diagnose efficiently. It is 376 reported that the occurrence of bNAbs is more frequent in infants (>40%) (42,43) and children 377 378 (44) as compared to adults, where bNAbs development occurs in a rare subset of chronically infected individuals. A potent protective antibody response in infants is governed by multivariant 379 infections in perinatally acquired HIV-1 (42), with an improvement in bNAb response upon 380 initiation of combined antiretroviral therapy (cART) (45). Hence, early detection of MCT is 381 essential for the initiation of cART in perinatal HIV-1 infections. Standard serology tests such as 382 ELISA and Western blot are not suitable for detecting HIV-1 infection in infants (below the age of 383 18 months), as the circulating maternal antibodies could lead to erroneous interpretation. 384

It is made available under a CC-BY-NC-ND 4.0 International license .

In this study, we have developed a CRISPR/Cas12a-based assay for rapid, sensitive, and specific 385 detection of HIV-1 clade C. Herein, all assay components are optimized for setting up the 386 387 preamplification by isothermal RPA and CRISPR/Cas12a based cleavage reaction in a single tube at 39°C for 45 mins, without the need of any intermediate purification or extraction step, thus 388 enabling robust molecular detection of HIV-1. The UV visual readout, fluorescence-based readout, 389 and adaptability into a lateral flow dipstick-based detection assay demonstrate the versatility and 390 employability of the CRISPR/Cas12a-based HIV-1 detection assay developed as a potential point-391 of-care diagnostic test. High mutagenesis in HIV-1 is attributed to high genetic variation, which 392 makes it difficult to target using the CRISPR/Cas12a system. Conserved regions (pol) in the HIV-393 1 genome were identified by aligning 86 HIV-1 sequences from Indian clade C infections. A 394 crRNA targeting a highly conserved region in the Pol gene of the HIV-1 genome was designed and 395 utilized in the assay for efficient detection of HIV-1. The assay was evaluated for its ability to 396 distinguish the presence or absence of HIV-1 nucleic acid by testing various HIV-1 positive (patient 397 cDNA and HIV genome plasmids) and HIV-1 negative samples (healthy controls, viral disease 398 controls, and NTCs) and AFU threshold range was established using ROC curve. A range of AFU 399 400 threshold value between 341-800 was used to distinguish positives from negatives efficiently, with any AFU values of the test samples less than 341 and greater than 800 determined as negative or 401 positive for the assay, respectively, and AFU values of the test samples in between 341-800 are 402 classified as result inconclusive. Samples with AFU readouts between 341-800 should be 403 reassessed using RT-PCR. Evaluating the assay performance with an optimal AFU threshold of 404 596 with an ROC AUC of 0.996 yielded 96% sensitivity and 92.65% specificity, implying that the 405 assay is efficient in the detection of HIV-1C in the tested samples. However, on testing disease 406 control samples (of Influenza, RSV, Parvovirus, Parainfluenza, CMV, and HBV), our assay yielded 407 AFU values between 341-800, suggesting an increase in nonspecific background fluorescence. 408 This implies that test samples (including those with viral infection other than HIV-1) with a tested 409 AFU value between 341-800 should be validated by RT-PCR to confirm the presence of HIV-1C 410 and or other viral nucleic acid. Further, our assay specifically detects HIV-1 Indian Clade-C and 411 not Clade B, which is the other major infecting clade of HIV-1 worldwide, hence shows that clade-412 specific crRNA could be designed for HIV-1, which may aid in screening for HIV-1 clade 413 distinction in a geographical location. 414

With 96.43% sensitivity (27/28) in the detection of HIV-1 in infants, the assay may serve as a 415 potential alternative to the serology tests, which are inefficient to test perinatal HIV-1 infection. 416 Although the whole nucleic acid PCR/qRT-PCR in dried blood spots (DBS) from heel prick is one 417 of the widely employed methods for HIV-1 detection in infants, it is less sensitive as compared to 418 direct sera detection and requires a 2-3 hours nucleic acid extraction procedure followed by 2-3 419 hours of qRT-PCR reaction (46). Hence, a high turnaround time and difficulty in extracting nucleic 420 acid from DBS leads to false positives and may require multiple sampling for validation of test in 421 infants. On the contrary, our assay requires 200-300µl of whole blood sample for viral RNA 422 423 extraction and cDNA preparation. The steps are the same as those in the DBS-qRT-PCR method, of 1 hour duration. The cDNA extracted can be directly used to detect HIV-1 in the test samples 424 using the assay developed with a turnaround time of 45 minutes, hence involving fewer steps and 425 time. 426

- 427 Similar CRISPR/Cas12a-based HIV-1 detection assays have been developed for the specific
- 428 detection of Chinese clade B and circulating recombinant forms (CRFs) (47), that target a distantly
- 429 conserved pol region compared to the Indian clade C pol gene conserved sequence used in our
- 430 assay. There are a few limitations of our assay, such as the viral RNA needs to be prior converted
- 431 to cDNA as additional steps before the assay, since the template for the CRISPR-Cas12a based
- 432 assay reaction is cDNA and the limit of detection of the assay remains to be determined in terms
- 433 of least number of detectable HIV-1 copies in the clinical test samples. There is scope to further
- 434 simplify the steps in the present CRISPR/Cas12a-based HIV-1 detection assay and overcome the
- 435 requirement of an additional step of viral cDNA synthesis by optimizing an all-in-one RT CRISPR-
- 436 Cas12a assay using MMLV reverse transcriptase, that can operate at 37-40°C (hence compatible
- 437 to the assay conditions), to directly detect HIV-1 RNA targets using sera as starting material. Thus,
- 438 such CRISPR/Cas12a-based detection assay systems demonstrate the potential to be developed
- 439 into true, handheld, point-of-care nucleic acid tests.
- 440 In summary, we have developed a robust CRISPR/Cas12a-based detection assay for clade C HIV-
- 1. Further testing of a large number of clinical samples using this lateral flow-based detection
- 442 method is warranted to evaluate the potential of the assay for point-of-care HIV-1 C molecular
- 443 diagnostics in resource-limited settings.

It is made available under a CC-BY-NC-ND 4.0 International license .

Acknowledgments 444

We are thankful to all the study subjects who participated in this study. We thank the NIH AIDS 445

Reagent program for providing HIV-genome-carrying IMCs plasmids. This work was funded by 446

the Department of Biotechnology (DBT), India (Project Code BT/GET/119/SP31652/2020). The 447

Junior Research Fellowship (December 2021–December 2023) and Senior Research Fellowship 448

(December 2023–Present) to H.B. was supported by the Department of Biotechnology (DBT), 449

India. 450

451

Author contributions 452

- A.G. performed the experiments and assay standardizations and finalized the manuscript. 453
- H.B. performed the experiments and assay standardizations, analyzed the data, and finalized the 454 manuscript. 455
- N.M. conceptualized the study, designed the crRNAs, and provided inputs for troubleshooting 456
- throughout the study. 457
- S.S. conceptualized the study, prepared the cDNA from the patient sera, and helped with assay 458 troubleshooting.
- 459
- T.B. helped with assay troubleshooting. 460
- M.K. helped with the statistical analysis. 461
- M.B. provided the viral disease control samples to test the specificity of the assay. 462
- B.K.D. provided the immunological data of the HIV-1-infected infants. 463
- R.L. provided the samples of HIV-1 infected infants and provided patient care and management. 464
- Su.S and K.L. conceptualized and designed the study, edited, revised, and finalized the manuscript. 465 466

Competing interests 467

The authors declare no competing interests. 468

It is made available under a CC-BY-NC-ND 4.0 International license .

469 **References**

- 470 1. Global HIV & AIDS statistics Fact sheet [Internet]. Available from:
- 471 https://www.unaids.org/en/resources/fact-sheet
- Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic
 subtypes and recombinants in 2004. AIDS Lond Engl. 2006 Oct 24;20(16):W13-23.
- 474 3. Kim J, Vasan S, Kim JH, Ake JA. Current approaches to HIV vaccine development: a narrative review. J
 475 Int AIDS Soc. 2021 Nov;24(S7):e25793.
- Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral Drugs for
 Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International
 Antiviral Society–USA Panel. JAMA. 2023 Jan 3;329(1):63.
- 479 5. Yilmaz G. Diagnosis of HIV infection and laboratory monitoring of its therapy. J Clin Virol Off Publ Pan
 480 Am Soc Clin Virol. 2001 Jun;21(3):187–96.
- Yamazaki S, Kondo M, Sudo K, Ueda T, Fujiwara H, Hasegawa N, et al. Qualitative Real-Time PCR
 Assay for HIV-1 and HIV-2 RNA. Jpn J Infect Dis. 2016 Sep 21;69(5):367–72.
- Noorbazargan H, Nadji SA, Samiee SM, Paryan M, Mohammadi-Yeganeh S. New design,
 development, and optimization of an in-house quantitative TaqMan Real-time PCR assay for HIV-1
 viral load measurement. HIV Clin Trials. 2018 Apr;19(2):61–8.
- 486 8. Technical Update for HIV Nucleic Acid Tests Approved for Diagnostic Purposes [Internet]. Available
 487 from: https://www.cdc.gov/hiv/guidelines/recommendations/technical-update-for-hiv.html
- 488 9. National Guidelines for HIV Testing [Internet]. National AIDS Control Organization; Available from:
 489 https://naco.gov.in/sites/default/files/National_Guidelines_for_HIV_Testing_21Apr2016.pdf
- 10. Nagamine K, Hase T, Notomi T. Accelerated reaction by loop-mediated isothermal amplification using
 loop primers. Mol Cell Probes. 2002 Jun;16(3):223–9.
- 492 11. Zhao J, Chang L, Wang L. Nucleic acid testing and molecular characterization of HIV infections. Eur J
 493 Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2019 May;38(5):829–42.
- 494 12. Manual on Paediatric HIV Care and Treatment for District Hospitals: Addendum to the Pocket Book
 495 of Hospital Care of Children. Geneva: World Health Organization; 2011. 6, Diagnosis of HIV infection
 496 in infants and children. [Internet]. World Health Organization; Available from:
 497 https://www.ncbi.nlm.nih.gov/books/NBK304129/
- 498 13. Ceffa S, Luhanga R, Andreotti M, Brambilla D, Erba F, Jere H, et al. Comparison of the Cepheid
 499 GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and
 500 detecting HIV-1 infection. J Virol Methods. 2016 Mar;229:35–9.
- Amitai G, Sorek R. CRISPR-Cas adaptation: insights into the mechanism of action. Nat Rev Microbiol.
 2016 Feb;14(2):67–76.

- Li SY, Cheng QX, Wang JM, Li XY, Zhang ZL, Gao S, et al. CRISPR-Cas12a-assisted nucleic acid
 detection. Cell Discov. 2018;4:20.
- Li SY, Cheng QX, Liu JK, Nie XQ, Zhao GP, Wang J. CRISPR-Cas12a has both cis- and trans-cleavage
 activities on single-stranded DNA. Cell Res. 2018 Apr;28(4):491–3.
- 507 17. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding
 508 unleashes indiscriminate single-stranded DNase activity. Science. 2018 Apr 27;360(6387):436–9.
- 509 18. Feng Z, Kong D, Jin W, He K, Zhao J, Liu B, et al. Rapid detection of isocitrate dehydrogenase 1
 510 mutation status in glioma based on Crispr-Cas12a. Sci Rep. 2023 Apr 7;13(1):5748.
- Lobato IM, O'Sullivan CK. Recombinase polymerase amplification: Basics, applications and recent
 advances. Trends Anal Chem TRAC. 2018 Jan;98:19–35.
- Daher RK, Stewart G, Boissinot M, Bergeron MG. Recombinase Polymerase Amplification for
 Diagnostic Applications. Clin Chem. 2016 Jul;62(7):947–58.

21. Chen J, Huang Y, Xiao B, Deng H, Gong K, Li K, et al. Development of a RPA-CRISPR-Cas12a Assay for
Rapid, Simple, and Sensitive Detection of Mycoplasma hominis. Front Microbiol. 2022 Apr
8;13:842415.

- 518 22. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with
 519 CRISPR nucleases. Nat Protoc. 2019 Oct;14(10):2986–3012.
- Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR-Cas12-based detection of
 SARS-CoV-2. Nat Biotechnol. 2020 Jul;38(7):870–4.

522 24. Fozouni P, Son S, Díaz de León Derby M, Knott GJ, Gray CN, D'Ambrosio MV, et al. Amplification-free
523 detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell. 2021 Jan
524 21;184(2):323-333.e9.

- 525 25. Li L, Li S, Wu N, Wu J, Wang G, Zhao G, et al. HOLMESv2: A CRISPR-Cas12b-Assisted Platform for
 526 Nucleic Acid Detection and DNA Methylation Quantitation. ACS Synth Biol. 2019 Oct 18;8(10):2228–
 527 37.
- 528 26. Wang J, Cai K, He X, Shen X, Wang J, Liu J, et al. Multiple-centre clinical evaluation of an ultrafast
 529 single-tube assay for SARS-CoV-2 RNA. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.
 530 2020 Aug;26(8):1076–81.
- 531 27. Yin L, Man S, Ye S, Liu G, Ma L. CRISPR-Cas based virus detection: Recent advances and perspectives.
 532 Biosens Bioelectron. 2021 Dec 1;193:113541.
- 533 28. Bahrulolum H, Tarrahimofrad H, Rouzbahani FN, Nooraei S, Sameh MM, Hajizade A, et al. Potential
 534 of CRISPR/Cas system as emerging tools in the detection of viral hepatitis infection. Virol J. 2023 May
 535 8;20(1):91.
- Ding X, Yin K, Li Z, Lalla RV, Ballesteros E, Sfeir MM, et al. Ultrasensitive and visual detection of SARS CoV-2 using all-in-one dual CRISPR-Cas12a assay. Nat Commun. 2020 Sep 18;11(1):4711.

It is made available under a CC-BY-NC-ND 4.0 International license .

S38 30. Chen C, Li XN, Li GX, Zhao L, Duan SX, Yan TF, et al. Use of a rapid reverse-transcription recombinase
aided amplification assay for respiratory syncytial virus detection. Diagn Microbiol Infect Dis. 2018
Feb;90(2):90–5.

- 541 31. Ding R, Long J, Yuan M, Zheng X, Shen Y, Jin Y, et al. CRISPR/Cas12-Based Ultra-Sensitive and Specific
 542 Point-of-Care Detection of HBV. Int J Mol Sci. 2021 May 3;22(9):4842.
- 543 32. Low SJ, O'Neill MT, Kerry WJ, Krysiak M, Papadakis G, Whitehead LW, et al. Rapid detection of
 544 monkeypox virus using a CRISPR-Cas12a mediated assay: a laboratory validation and evaluation
 545 study. Lancet Microbe. 2023 Oct;4(10):e800–10.
- Sun Y, Yu L, Liu C, Ye S, Chen W, Li D, et al. One-tube SARS-CoV-2 detection platform based on RT-RPA
 and CRISPR/Cas12a. J Transl Med. 2021 Feb 16;19(1):74.
- 548 34. Souf S. Review article Recent advances in diagnostic testing for viral infections. Biosci Horiz. 2016;9.
- 35. Ahn SJ, Baek YH, Lloren KKS, Choi WS, Jeong JH, Antigua KJC, et al. Rapid and simple colorimetric
 detection of multiple influenza viruses infecting humans using a reverse transcriptional loopmediated isothermal amplification (RT-LAMP) diagnostic platform. BMC Infect Dis. 2019
 Dec;19(1):676.
- 55336. Tomita N, Mori Y, Kanda H, Notomi T. Loop-mediated isothermal amplification (LAMP) of gene554sequences and simple visual detection of products. Nat Protoc. 2008 May;3(5):877–82.
- 37. Centers for Disease Control and Prevention (U.S.), Bernard M. B, Association of Public Health
 Laboratorie, S. Michele O, Laura G. W, Berry B, et al. Laboratory testing for the diagnosis of HIV
 infection : updated recommendations [Internet]. Centers for Disease Control and Prevention; 2014
 Jun [cited 2024 Nov 15]. Available from: http://stacks.cdc.gov/view/cdc/23447
- 38. Bui TI, Farnsworth CW, Anderson NW. Evaluation of a point-of-care rapid HIV antibody test with
 insights into acute HIV symptomatology in a population with low prevalence. Theel ES, editor. J Clin
 Microbiol. 2024 Sep 11;62(9):e00620-24.
- S62 39. Krasowski MD, Wier D, Smith S, Riedel A, Lauseker-Hao Y, Kelner M, et al. Real-World Clinical
 S63 Performance Evaluation of a Fourth-Generation HIV Antigen/Antibody Differentiation Test. J Appl Lab
 S64 Med. 2021 Nov 1;6(6):1417–32.
- 40. Guiraud V, Ciczora Y, Cardona M, Defer C, Gréaume S, Nogues D, et al. Sensitivity and specificity of
 the new Bio-Rad HIV screening test, Access HIV combo V2. Hayden R, editor. J Clin Microbiol. 2024
 May 8;62(5):e00095-24.
- 41. Patel P, Bennett B, Sullivan T, Parker MM, Heffelfinger JD, Sullivan PS. Rapid HIV screening: Missed
 opportunities for HIV diagnosis and prevention. J Clin Virol. 2012 May;54(1):42–7.
- 42. Mishra N, Makhdoomi MA, Sharma S, Kumar S, Dobhal A, Kumar D, et al. Viral Characteristics
 Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected
 Monozygotic Pediatric Twins. Sundquist WI, editor. J Virol. 2019 Sep;93(17):e00654-19.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 43. Goo L, Chohan V, Nduati R, Overbaugh J. Early development of broadly neutralizing antibodies in
 HIV-1-infected infants. Nat Med. 2014 Jun;20(6):655–8.
- 44. Makhdoomi MA, Khan L, Kumar S, Aggarwal H, Singh R, Lodha R, et al. Evolution of cross-neutralizing
 antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral
 therapy-naïve children from India. J Gen Virol. 2017 Jul;98(7):1879–91.
- 45. Kumar S, Batra H, Singh S, Chawla H, Singh R, Katpara S, et al. Effect of combination antiretroviral
 therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected
 children. J Gen Virol. 2020 Dec;101(12):1289–99.
- 46. Rutstein SE, Kamwendo D, Lugali L, Thengolose I, Tegha G, Fiscus SA, et al. Measures of viral load
 using Abbott RealTime HIV-1 Assay on venous and fingerstick dried blood spots from providercollected specimens in Malawian District Hospitals. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2014
 Aug;60(4):392–8.
- 47. Zhao J, Ao C, Wan Z, Dzakah EE, Liang Y, Lin H, et al. A point-of-care rapid HIV-1 test using an
 isothermal recombinase-aided amplification and CRISPR Cas12a-mediated detection. Virus Res. 2021
 Oct 2;303:198505.

588



Figure 1: The CRISPR/Cas12a-based HIV-1 detection assay. a) Schematic of the CRISPR/Cas12a-based assay workflow. Viral RNA extraction followed by cDNA preparation from the serum samples yields the target nucleic acid for the assay. The RPA and CRISPR/Cas12a cleavage reaction co-occur in a single tube to aid in the detection of target nucleic acid. Cleaved reporter signal can be detected by UV lamp/transilluminator (visual detection) and multimode fluorescence reader (fluorescence detection for semi-quantitation of the assay). **b)** HIV-1 Genome map depicting the RPA amplicon region carrying the crRNA sequence. The region marked in red represents the RPA amplicon (183bps) with HXB2 coordinates 2328-2509 bps; RPA primers labelled in the purple and green region represent the crRNA sequence.



Figure 2: Evaluation of the CRISPR/Cas12a-based assay for detecting the HIV-1 Indian Clade C in clinical samples. The CRISPR/Cas12a-based HIV-1 clade C detection assay was validated using positive controls. **a)** UV transilluminator image and **b)** fluorescence readout of the assay performed for the AIIMS748 (HIV-1 positive donor) cDNA at different dilutions and in the HIV-1 genome plasmids (93IN999 and 93IN905). Lane 1- NTC, lane 2- 93IN999, lane 3 -93IN905, lane 4- AIIMS748(1:10) dilution, lane 5-AIIMS748(1:5) dilution, lane 6-AIIMS748(1:3) dilution. The CRISPR/Cas12a-based assay results were recorded using visual (UV transilluminator) and fluorescence (AFU) readout. The fluorometer readings of fluorescence emission were recorded as AFU (Arbitrary fluorescence unit) at excitation at 488nm and emission

It is made available under a CC-BY-NC-ND 4.0 International license .

at 520nm. **c-f)** The ROC curves are plotted for the evaluation of the assay performance and to determine optimal AFU threshold values for distinguishing between an HIV-positive and negative sample. The ROC analysis was done between clinical samples groups; Positive vs Healthy (AUC-1.000), Positive vs Negative (AUC-0.992), Positive vs Healthy and Negative (0.996), Positive vs DiseaseControl (AUC-0.958) to determine the optimal threshold by Youden's index as 341, 725, 596 and 800 respectively. The optimal AFU obtained from ROC curves from the respective groups were used to evaluate the sensitivity and specificity of the assay.



Figure 3: Performance of the CRISPR/Cas12a-based assay in clinical samples. a) Schematic of assay performance evaluation using true positives-50 (41 HIV positive plasma, 9 HIV-1 genome plasmid 93IN999 replicates) and true negatives- 68 (25 NTC replicates, 31 healthy donor plasma samples, 12 viral disease control DNA/RNA samples), total-118 samples, to plot an ROC curve and determine the optimal AFU threshold and evaluate the sensitivity and specificity of the assay in detecting HIV-1C in clinical samples. **b)** Comparison of the AFU values for the different clinical samples tested for the presence of HIV-1 using the CRISPR/Cas12a-based detection assay. AFU

It is made available under a CC-BY-NC-ND 4.0 International license .

threshold values 800 (highest) and 341(lowest), determined using the ROC curve, were used to distinguish the positive and negative results of the assay. **c-f**) The sensitivity and specificity of the assay were evaluated to determine the positive and negative samples efficiently using the different AFU threshold values obtained from the ROC curve analysis. AFU threshold values of 341, 725, 596, and 800 were used to evaluate the sensitivity and specificity of the assay, respectively. The positive group includes HIV-1 positive clinical samples and positive genome plasmid replicates, and the negative group consists of the healthy controls, NTCs, and viral disease controls. Dots represent the AFU values plotted against the left y-axis, and Bars represent the sensitivity or specificity values plotted against the right y-axis.

It is made available under a CC-BY-NC-ND 4.0 International license .

	ROC Curve		Confusion Matrix (All Samples)			Performance Metric		
CRISPR Cas12a-	AUC	Optimal AFU Threshold (Youden's Index)	Tested\True	qRT-PCR/Serology		Sensitivity	Snecificity	
based assay results (Fluorescence readout)				Positive	Negative	(%, 95% CI)	(%, 95% CI)	Kappa Value
Positive vs Healthy	1.000	341.00	Positive	50	0	100.00 (100.00- 100.00)	77.94 (67.65-86.76)	0.75
Controls			Negative	15	53			
Positive vs Negative	0.992	725.00	Positive	47	3	94.00 (86.00-100.00)	97.03 (92.65-100.00)	0.913
Controls (NTCs)			Negative	2	66			
Positive vs Healthy + Negative	0.996	596.00	Positive	48	2	96.00 (90.00-100.00)	92.65 (85.29-98.53)	0.879
Controls			Negative	5	63			
Positive vs Disease	0.958 8	800.00	Positive	44	6	88	100.00	0.804
Controls		800.00	Negative	0	68	(78.00-96.00)	(100.00- 100.00)	0.894

Table 1: Performance characteristics of the CRISPR/Cas12a-based HIV-1 C detection assay.



Figure 4: Specificity of the CRISPR/Cas12a-based assay for detecting HIV-1 Indian clade C. The specificity of the assay was evaluated against different HIV-1 negative biological samples, and the output in the form of UV transilluminator (visual) readout and fluorescence detector

It is made available under a CC-BY-NC-ND 4.0 International license .

readout AFU (Arbitrary fluorescence unit) was compared across all samples. **a**) Evaluation of assay specificity using viral disease control samples n=15; Influenza virus RNA sample from patient plasma, Respiratory syncytial virus (RSV) RNA sample from patient plasma, Parvovirus positive DNA sample from patient plasma, Human Parainfluenza virus (HPIV) RNA sample from patient plasma, CMV positive DNA sample from patient plasma and HBV genome plasmid replicates. **b**) Evaluation of clade specificity of the detection assay in distinguishing HIV-1 Indian clade C infections using n=7 HIV-1 clade B serum samples. **c**) Evaluation of assay specificity using n=31 Healthy donor serum samples. The assay specificity was validated by using positive controls (HIV-1 Indian clade C genome carrying plasmid 93IN999 and serum sample of Indian clade C infected patient AIIMS748) for HIV-1 Indian clade C detection along with the different negative controls tested. The fluorometer readings of fluorescence emission were recorded as AFU (Arbitrary fluorescence unit) at excitation at 488nm and emission at 520nm. AFU threshold values 800 (highest) and 341(lowest) were used to distinguish positive and negative results of the assay.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 5: The lateral flow CRISPR/Cas12a-based HIV-1C detection assay. a) Schematic of Lateral flow strip-based detection of the CRISPR/Cas12a assay. ssDNA-FAM-Biotin reporter, upon activation of collateral cleavage activity of Cas12a in the presence of HIV-1 target sequence, releases the FAM molecule, which is bound by anti-FAM Gold nanoparticles and is captured by anti-rabbit antibody on the test line. In the absence of an HIV-1 target sequence, the uncleaved probe gets captured at the control line via streptavidin-biotin interaction. b) Detection of HIV by the CRISPR/Cas12a-based detection assay using lateral flow strips to optimize the assay into a point-of-care CRISPR/Cas12a-based lateral flow assay (LFA). HIV genome plasmid 93IN999 was used to optimize lateral flow strip-based readout of the assay with 0.009μ M ssDNA-FAM-biotin probe concentration. A dark band on the test line represents a positive detection with no detection on the test line in the corresponding NTC strip.